Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
暂无分享,去创建一个
L. Fallowfield | Y. Fujiwara | J. Jassem | A. Stopeck | R. Bell | G. Steger | C. Vogel | A. Brufsky | Miguel Martín | A. Paterson | I. Diel | A. Braun | A. Eniu | H. Bourgeois | D. Ritchie | K. Chung | R. Dansey | M. Fan | Q. Jiang
[1] A. Stopeck,et al. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States , 2012, Journal of medical economics.
[2] J. Weissfeld,et al. Factors associated with mortality after breast cancer metastasis. , 2011, Journal of Clinical Oncology.
[3] G. Scagliotti,et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[5] Y. Fujiwara,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] I. Ray-Coquard,et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues , 2010, Breast Cancer Research and Treatment.
[7] D. Castellano,et al. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain , 2010, European journal of cancer care.
[8] G. Hortobagyi,et al. Survival differences among women with de novo stage IV and relapsed breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] I. Diel. Bisphosphonates in Breast Cancer Patients with Bone Metastases , 2010, Breast Care.
[10] M. Leahy,et al. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease , 2009 .
[11] Liying Zhang,et al. Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. , 2009, European journal of cancer.
[12] X. Badia,et al. Impact of skeletal complications on patients’ quality of life, mobility, and functional independence , 2008, Supportive Care in Cancer.
[13] K. Kavanagh,et al. Bisphosphonates , 2007, Annals of the New York Academy of Sciences.
[14] I. Diel,et al. Adverse effects of bisphosphonates: current issues. , 2007, The journal of supportive oncology.
[15] R. Coleman. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity , 2006, Clinical Cancer Research.
[16] Y. Ohashi,et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Cameron,et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration , 2005, British Journal of Cancer.
[18] R. Bell,et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer , 2004, Pain.
[19] D. Neuberg,et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. , 2004, Journal of clinical epidemiology.
[20] M. Krzakowski,et al. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.
[21] K. Weinfurt,et al. Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions , 2004, Medical care.
[22] David Cella,et al. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation , 2003, Health and quality of life outcomes.
[23] A. Howell,et al. Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma , 2003, Cancer.
[24] M. Krzakowski,et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Howell,et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. , 2001, Cancer journal.
[26] L. Hofbauer,et al. Receptor activator of nuclear factor‐κB ligand and osteoprotegerin , 2001 .
[27] D S Tulsky,et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] S. Adami,et al. The acute-phase response after bisphosphonate administration , 1987, Calcified Tissue International.
[29] A. S. Appel,et al. ACUTE RENAL FAILURE , 1967, Advances in Experimental Medicine and Biology.
[30] G. Hortobagyi,et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] M. Perazella,et al. Bisphosphonate nephrotoxicity. , 2008, Kidney international.
[32] M. Tabrizi,et al. Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.